Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models
暂无分享,去创建一个
Joshua E. Lewis | Sameer H. Halani | D. Brat | D. Gutman | Congzheng Song | Safoora Yousefi | M. Amgad | José E. Velázquez Vega | L. Cooper | F. Amrollahi | Chengliang Dong | Fatemeh Amrollahi | S. Halani | Coco Dong | Fatemeh Amrollahi
[1] J. Sneep,et al. With a summary , 1945 .
[2] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[3] D Faraggi,et al. A neural network model for survival data. , 1995, Statistics in medicine.
[4] P. Lapuerta,et al. Comparison of the performance of neural network methods and Cox regression for censored survival data , 2000 .
[5] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[6] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] Yannis Dimopoulos,et al. Use of some sensitivity criteria for choosing networks with good generalization ability , 1995, Neural Processing Letters.
[8] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[9] Q. Cui,et al. Identification of high-quality cancer prognostic markers and metastasis network modules , 2010, Nature communications.
[10] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[11] J. Uhm,et al. The transcriptional network for mesenchymal transformation of brain tumours , 2010 .
[12] Hans Christian Pedersen,et al. Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy , 2010, Breast Cancer Research.
[13] Ganesh Rao,et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. , 2011, Genes & development.
[14] Trevor Hastie,et al. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.
[15] Jasper Snoek,et al. Practical Bayesian Optimization of Machine Learning Algorithms , 2012, NIPS.
[16] Pascal Vincent,et al. Representation Learning: A Review and New Perspectives , 2012, IEEE Transactions on Pattern Analysis and Machine Intelligence.
[17] George W. Sledge,et al. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.
[18] Rasool Fakoor,et al. Using deep learning to enhance cancer diagnosis and classication , 2013 .
[19] Franziska Michor,et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. , 2014, Cancer cell.
[20] Samy Lamouille,et al. Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.
[21] Ruben Martinez-Cantin,et al. BayesOpt: a Bayesian optimization library for nonlinear optimization, experimental design and bandits , 2014, J. Mach. Learn. Res..
[22] Hemant Ishwaran,et al. Random survival forests for competing risks. , 2014, Biostatistics.
[23] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.
[24] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[25] Dimitrios I. Fotiadis,et al. Machine learning applications in cancer prognosis and prediction , 2014, Computational and structural biotechnology journal.
[26] Wyeth W. Wasserman,et al. Deep Feature Selection: Theory and Application to Identify Enhancers and Promoters , 2015, RECOMB.
[27] Geoffrey E. Hinton,et al. Deep Learning , 2015, Nature.
[28] Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas The Cancer , 2015 .
[29] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[30] B. Frey,et al. Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning , 2015, Nature Biotechnology.
[31] N. Linder,et al. Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples , 2016, Journal of pathology informatics.
[32] L. V. van't Veer,et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.
[33] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[34] Congzheng Song,et al. Learning Genomic Representations to Predict Clinical Outcomes in Cancer , 2016, ArXiv.
[35] Guigang Zhang,et al. Deep Learning , 2016, Int. J. Semantic Comput..
[36] Shamim Nemati,et al. Optimal medication dosing from suboptimal clinical examples: A deep reinforcement learning approach , 2016, 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[37] Y. Kluger,et al. Deep Survival: A Deep Cox Proportional Hazards Network , 2016, ArXiv.
[38] Jinfeng Zou,et al. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer. , 2016, JAMA oncology.
[39] Wyeth W. Wasserman,et al. Deep Feature Selection: Theory and Application to Identify Enhancers and Promoters , 2015, RECOMB.
[40] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.
[41] Samy Bengio,et al. Understanding deep learning requires rethinking generalization , 2016, ICLR.